{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-032184","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.674311+00:00","generated_at":"2026-05-17T01:34:02.697972+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"CervoMed appoints former McKinsey Senior Partner David Quigley to Board","bullets":["David Quigley appointed to board effective Oct 27, 2025; board expanded from 7 to 8 members.","Quigley was McKinsey Senior Partner (2010-2025) leading Private Capital and Life Sciences practices.","Granted option to buy 16,200 shares at $7.02, vesting in 36 equal monthly installments.","Company expects FDA feedback on Phase 3 trial design for neflamapimod in DLB in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-032184","json":"https://secwatch.observer/filing/0001437749-25-032184.json","markdown":"https://secwatch.observer/filing/0001437749-25-032184.md","text":"https://secwatch.observer/filing/0001437749-25-032184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925032184/0001437749-25-032184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925032184/crvo20251029c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:34:02.697972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}